Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 1,194 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,194 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $55,616.52. Following the completion of the sale, the senior vice president owned 165,445 shares of the company’s stock, valued at approximately $7,706,428.10. This trade represents a 0.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Paula Green also recently made the following trade(s):

• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total value of $9,434.88.

Twist Bioscience Stock Down 2.1%

Shares of NASDAQ TWST traded down $1.02 during mid-day trading on Thursday, reaching $47.10. The company had a trading volume of 2,162,437 shares, compared to its average volume of 1,485,586. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $54.74. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.78. The company has a market capitalization of $2.89 billion, a price-to-earnings ratio of -36.80 and a beta of 2.24. The stock has a fifty day moving average of $36.23 and a two-hundred day moving average of $31.84.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm’s revenue was up 16.9% compared to the same quarter last year. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TWST. Barclays raised their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday. Evercore ISI lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday. Finally, TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.88.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after acquiring an additional 302 shares during the last quarter. D.A. Davidson & CO. grew its position in shares of Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after purchasing an additional 305 shares during the last quarter. CWM LLC increased its stake in shares of Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares during the period. California State Teachers Retirement System boosted its stake in Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after purchasing an additional 442 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.